5050-41-9

Basic information

• Product Name: 1-(2-CHLOROETHYL)-PYRROLIDINE
• Synonyms: 1-(2-CHLOROETHYL)-PYRROLIDINE;N-(2-CHLOROETHYL)-PYRROLIDINE;PYRROLIDINE, 1-(2-CHLOROETHYL)-
• CAS NO: 5050-41-9
• Molecular Formula: C₆H₁₂ClN
• Molecular Weight: 133.62
• Mol File: 5050-41-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 170.5 °C at 760 mmHg
• Flash Point: 56.9 °C
• Appearance: /
• Density: 1.037 g/cm³
• Storage Temp.: 2-8°C
• PKA: 9.37±0.20(Predicted)
• CAS DataBase Reference: 1-(2-CHLOROETHYL)-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-CHLOROETHYL)-PYRROLIDINE(5050-41-9)
• EPA Substance Registry System: 1-(2-CHLOROETHYL)-PYRROLIDINE(5050-41-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 5050-41-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H12ClN/c7-3-6-8-4-1-2-5-8/h1-6H2

Upstream product

• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 2955-88-6 1-pyrrolidineethanol 

Downstream Products

• 94311-88-3 2-phenyl-2-[2]pyridyl-4-pyrrolidino-butyronitrile 
• 94864-64-9 1-(2-phenyl-4-pyrrolidino-butyryl)-piperidine 
• 47060-09-3 1-(3,3-diphenylpropyl)pyrrolidine 
• 59289-98-4 2,2-diphenyl-4-pyrrolidino-butyronitrile 
• 103207-02-9 1-(3-cyclohex-1-enyl-3-phenyl-propyl)-pyrrolidine 
• 874496-82-9 2-cyclohexyl-2-phenyl-4-pyrrolidino-butyronitrile 
• 95949-63-6 2,2-diphenyl-4-pyrrolidino-butyric acid dimethylamide 
• 102372-89-4 hydroxy-norborn-5-en-2-yl-phenyl-acetic acid-(2-pyrrolidino-ethyl ester) 
• 102700-84-5 hydroxy-norborn-5-en-2-yl-p-tolyl-acetic acid-(2-pyrrolidino-ethyl ester) 
• 56951-36-1 2-phenyl-4-pyrrolidino-butyronitrile 
• 4398-62-3 benzilic acid-(2-pyrrolidino-ethyl ester) 
• 36716-44-6 N-[2-(pyrrolidin-1-yl)ethyl]aniline 
• 124143-91-5 2,6-dimethyl-N-(2-pyrrolidino-ethyl)-aniline 
• 32776-22-0 1-(2-methylaminoethyl)pyrrolidine 

Relevant articles and documents

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease

The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD. Three series of compounds were developed by attaching the H3R pharmacophore to indanone-related MAO B motifs, leading to development of MAO B/H3R DTLs. Among synthesized indanone DTLs, compounds bearing the 2-benzylidene-1-indanone core structure showed MAO B preferring inhibition capabilities along with nanomolar hH3R affinity. Substitution of C5 and C6 position of the 2-benzylidene-1-indanones with lipophilic substituents revealed three promising candidates exhibiting inhibitory potencies for MAO B with IC50 values ranging from 1931 nM to 276 nM and high affinities at hH3R (Ki 50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36). Interestingly, IC50 determinations after preincubation of enzyme and DTLs revealed also nanomolar MAO B potency for 3e (MAO B IC50 = 232 nM), a structural isomer of 3f, and 3d (MAO B IC50 = 541 nM), suggesting time-dependent inhibition modes. Reversibility of inhibition for all three compounds were confirmed by dilution studies in excess of substrate. Thus, indanone-substituted derivatives are promising lead structures for the design of MAO B/hH3R DTLs as novel therapeutic approach of PD therapy.

ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES

This invention relates to pyrrolopyrimidine derivatives of formula (I): where R1, X, p, R4, R2and R3are as defined herein, and their use as pharmaceuticals.